Spectral AI GAAP EPS of -$0.11 beats by $0.03, revenue of $2.86M misses by $2.47M (NASDAQ:MDAI)

Spectral AI reported Q3 GAAP EPS of -$0.11, beating estimates by $0.03, but revenue of $2.86M missed by $2.47M, down 24.5% year-over-year. Shares fell 3.9% after hours.

Original reporting
Published Nov 10, 2026, 9:40 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 9:44 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$MDAI
Bearish
high confidence
Mentioned
$MDAI
Relevance
6/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$MDAIBearishMed
01

Why it matters

The earnings release provides the first public data on Q3 performance, confirming a revenue decline and modest EPS improvement, which drove a near‑4% after‑hours sell‑off.

02

Market read

The earnings miss is the primary catalyst for the stock's short‑term move; broader market impact is limited.

03

What to watch

Potential upcoming contracts or product launches not disclosed in this brief could mitigate the revenue shortfall.

Relevance 6/10Novelty 8/10Timing: after‑hours today

Background

Spectral AI is a NASDAQ‑listed AI‑focused microcap that recently showcased its DeepView platform at the Burn conference.

Company-level read

Ticker impact

$MDAIBearishHigh confidence
Context

Spectral AI reported Q3 GAAP EPS of -$0.11 (beat by $0.03) and revenue of $2.86M (miss by $2.47M), causing a 3.9% after‑hours decline.

Expected impact

downward pressure as investors price in the revenue shortfall

Evidence & confidence

Revenue fell 24.5% YoY and missed expectations by a sizable margin, while the EPS beat was minimal; the after‑hours price drop confirms negative market reaction.

Market effects

Highlights continued pressure on AI‑related microcaps amid weak revenue trends.

Limited to US small‑cap investors; no broader regional effect.

Minimal; microcap earnings rarely influence global markets.

Counterpoint

Despite the revenue miss, the EPS beat could signal improving cost control, offering a short‑term buying opportunity on the dip.

Key entities

  • Spectral AI, Inc.

    NASDAQ‑listed AI microcap reporting Q3 results.

Related articles

$MDAIMed

Spectral AI Announces 2026 Second Quarter Financial Results

Spectral AI, Inc. (MDAI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Spectral AI Announces 2026 Second Quarter Financial Results Company Continues to Advance Towards First Commercial Sales of the DeepView ® System for Burn Indication Strong Cash Position of $14.0 Million at June 30, 2026 DALLAS, TX – August 11, 2026 – Spectral AI, Inc

$MDAIMed

Spectral AI Names Darcy Bajko Chief Commercial Officer to Lead Global Sales Launch of FDA-Cleared DeepView® System for Burn Indication

Spectral AI, Inc. (Nasdaq: MDAI) appointed Darcy Bajko as Chief Commercial Officer effective July 31, 2026, to lead global sales for its FDA De Novo-cleared DeepView System for burn indication. The company said it aims to close its first commercial sales by year end 2026 and target adoption in US burn centers and emergency departments.

$DDOGHighAI 9/10

“Missing Forest-for-the-Trees”: Datadog Sinks 17% in a Week as Its Biggest AI Customer Cuts Back

Datadog (DDOG) stock fell 17% in a week after reporting 35% Q3 revenue growth to $1.2B but guiding Q4 revenue to $1.19-1.2B, roughly flat. The decline was driven by its largest AI customer reducing usage, though growth outside this customer is accelerating. Cloudflare (NET) reported strong Q3 results and a rising Q4 outlook, suggesting the slowdown may be isolated. Datadog trades at 60x forward earnings, below its usual multiple.

$NOVTHighAI 8/10

Novanta (NOVT) Q3 2026 Earnings Call Transcript

Novanta (NOVT) reported Q3 2026 revenue of $305M, up 23%, with organic growth of 10%. Adjusted EBITDA rose 38% to $80M, and adjusted EPS increased 21% to $1.05. The company acquired Riverpoint Medical, expanding its medical end markets to 53% of revenue. Customer bookings grew 29%, and backlog reached $543M. Operating cash flow tripled year-over-year to $156M. Novanta expects full-year 2027 gross margin expansion and strong earnings growth, driven by new products and acquisitions.